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Summary 
Paroxysmal nocturnal hemoglobinuria (PNH) is a hemolytic disorder caused by a deficiency of 
biosynthesis of the glycosyl phosphatidylinositol (GPI)  anchor, but the biochemical defect is 
not completely understood. In the present study, we have analyzed affected cell lines established 
recently from two Japanese patients with PNH. Two lines of evidence indicate that these cells 
do not synthesize N-acetylglucosaminyl-phosphatidylinositol, the first intermediate in the GPI 
anchor biosynthesis. First, somatic cell hybridization analysis using Thy-l-deficient murine thymoma 
cell lines with known biochemical defects as fusion partners showed that the PNH cell lines 
belong to complementation class A, which is known not to synthesize N-acetylglucosaminyl- 
phosphatidylinositol. Second, analysis of in vitro glycolipid biosynthesis demonstrated that cell 
lysates of these PNH cell lines in fact did not support biosynthesis of N-acetylglucosaminyl- 
phosphatidylinositol. Thus, we have characterized for the first time the exact biochemical defect 
leading to PNH. 
p aroxysmal nocturnal hemoglobinuria (PNH) is a hema- 
tologic disorder caused by an acquired deficiency of the 
glycosyl phosphatidylinositol (GPI) anchor biosynthesis (1-4). 
Defidencies of GPI-anchored complement  regulatory proteins, 
decay-accelerating factor (DAF) and 20-kD homologous re- 
striction factor (CD59), both of which inhibit complement 
activation on the host cell surface and thereby protect host 
cells from destructive action of complement,  are causally related 
to intravascular hemolysis, a major clinical symptom (5). The 
deficiency  of GPI-anchored proteins is found in different 
lineages of hematopoietic cells including lymphocytes (6-9). 
It is, therefore, thought that a somatic mutation has occurred 
in the multipotential hematopoietic stem cell, which gives 
rise to affected blood cells and lymphocytes. Biosynthesis of 
the GPI anchor involves multiple reaction steps, being repre- 
sented  by  several complementation  classes of  GPI  an- 
chor-deficient mutant cell lines (10). Defects of many of them 
have been biochemically characterized (11-15). Cells of three 
different complementation classes, A, C, and H, do not syn- 
thesize an early intermediate, N-acetylglucosaminyl-phospha- 
tidylinositol (GlcNAc-PI), indicating that these early com- 
plementation classes define different genes, all of which must 
be necessary for biosynthesis of this glycolipid. Other classes, 
such as B and F, have defects in the later reaction steps. We 
recently established affected cell lines from two Japanese pa- 
tients with PNH (16). In the present study we demonstrated 
that those cell lines belong to the complementation class A. 
Analysis of glycolipid biosynthesis confirmed that those PNH 
cell lines in fact do not synthesize GlcNAc-PI. 
Materials and Methods 
Cells and Culture  GPI anchor-defident  cell lines (SS-I-, TK-I-, 
and TK-14-) and wild-type cell lines (SS-2  + and TK-4 +) estab- 
lished from two Japanese patients with PNH (patients SS and TK) 
were described  previously (16). Thy-l-deficient routine thymoma 
cell lines, BW5147(Thy-l-a),  S49(Thy-l-a),  AKRI(Thy-I-a), 
S1A(Thy-l-b), T1Ml(Thy-l-c),  AKR.I(Thy-I-d), BW5147(Thy- 
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(17-21). A Japanese Burkitt's lymphoma cell line, P32/Ishida (22), 
was a gift from Dr.  T. Seya (Center for Adult Diseases, Osaka, 
Japan) and a GPI anchor-deficient cell line, P32-2D2,  derived from 
P32/Ishida was established in our laboratory by ethylmethanesul- 
fonate treatment followed by flow-cytometric sorting of CD59- 
negative cells and cloning by limiting dilution. All cell lines were 
cultured in DMEM containing 10%  FCS. 
Complementation Analysis with Somatic Cell Fusion and Immuno- 
fluorescence Staining.  Cells  (1-5  x  1@ cells each) were washed 
with FCS-free DMEM containing 30 mM Hepes (pH 7.4) and fused 
with 50% polyethylene glycol 4000 in the Hepes-buffered,  FCS- 
free DMEM. Fused cells were cultured for 1-3 d and stained for 
surface expression of CD59. For this, biotinylated anti-CD59 mAb 
5H8 (a gift from Drs. M. Tomita and Y. Sugita, Showa University, 
Tokyo, Japan) was used in combination with PE-conjugated strep- 
tavidin (Biomeda, Foster City, CA). Complementation of surface 
expression of CD59 was assessed  by observing large heterokaryons 
under a fluorescent microscope. The complementation  analysis  with 
heterokaryons was used to avoid problems with chromosome segre- 
gation in interspecific hybrids. 
Biosynthesis of the GPI Anchor Intermediates.  Cell lysates were 
prepared as described previously (23). The lysates (107 cell equiva- 
lent) were incubated with 2 #Ci of UDP-6-[3H]GlcNAc  (Amer- 
ican Radiolabeled Chemicals,  St. Louis, MO) for 15 min at 37~ 
in the presence of tunicamycin (23). n-Butanol soluble lipid frac- 
tion was subjected to thin-layer chromatography on silica gel with 
a solvent consisting of chloroform, methanol, and 1 M NH4OH 
(10:10:3) (23). The gel was treated for fluorography.  Aliquots of 
the lipid fraction were treated with phosphatidylinositol-specific 
phospholipase  C  (PI-PLC)  and HNO2,  respectively,  to confirm 
presence of  PI and nonacetylated glucosamine (23). The lysates were 
also incubated with GDP-2-[3H]mannose  for 90 min at 37~  as 
described previously (24). In vivo labeling of cells with [3H]mannose 
was done as described  (24). 
Results 
Determination of the Complementation Class of the Cell Lines 
Established from  Patients with PNH.  The SS-1-  cells were 
fused with Thy-l-deficient murine thymoma cells  of com- 
plementation classes  A,  B,  C,  D,  E,  F,  and H,  and heter- 
okaryons were assessed for surface expression of CD59 (Fig. 
i  and Table 1). Surface expression of CD59 was complemented 
on fusion with classes  B, C, D, E, F, and H, but not with 
class A, indicating that SS-1-  cells belong to complementa- 
tion class  A.  Further analysis with two other murine class 
A thymoma cell lines confirmed this result (Table 1). A similar 
study performed with another PNH cell line demonstrated 
that TK-14-  cells  also belong to class  A  (Table  1).  Fusion 
between SS-1-  and TK-14-  cells  did not complement sur- 
face expression  of CD59,  confirming that  these PNH  cell 
lines that were established from different patients belong to 
Figure 1.  Complementation of deficient surface  expression of CD59 on SS-1- cells on fusion with class B, C, D, E, F, and H cells, but not class 
A cells. SS-1- cells were fused with Thy-l=deficient  routine thymoma cell lines of complementation  class A (I), class B (2), class C (3), class D (4), 
class E (not shown), class  F (5), or class H (6). Heterokaryons  were assessed  for complementation  by surface  staining  of CD59. In each panel, fluorescent 
micrograph is on the left and phase-contrast micrograph is on the right. 
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Cell Lines 
Fusion partners  Class  SS-1-  TK-14-  P32-2D2 
BW5147 (Thy-l-a)  A  -  *  -  + * 
S1A (Thy-l-b)  B  +  +  ND 
TIM1  (Thy-1- c)  C  +  +  ND 
AKR1 (Thy-l-d)  D  +  +  ND 
BW5147.3  (Thy-l-e)  E  +  +  ND 
EL-4 (Thy-1- f)  F  +  +  ND 
$49.1 (Thy-l-h)  H  +  +  ND 
AKR1 (Thy-l-a)  A  -  ND  ND 
$49  (Thy-l-a)  A  -  ND  ND 
SS-1-  -  -  + 
TK-14-  -  -  + 
P32-2D2  +  +  - 
SS-1-, TK-14-, and P32-2D2 cells were fused  with cell lines listed  and 
assessed for surface expression of CD59. 
* Deficiency not complemented. 
Deficiency complemented. 
Figure 2.  Biosynthesis  of glucosamine-containing  glycolipids.  Cell  ly- 
sates of cell  lines  established  from  patients  with PNH were  incubated  with 
UDP-6-[3H]GIcNAc at 37~  for 15 rain. The lipid  fraction  was subjected 
to thin-layer  chromatography  and fluorographic  analysis.  Lane  1, TK-1-  ; 
lane 2, TK-4+; lane 3, TK-14-; lane 4, SS-2+; lane 5, SS-1-. 
the same class. Surface expression of CD59 was complemented 
when class A murine thymoma cells were fused with a GPI 
anchor-deficient human cell line, P32-2D2  (Table  1).  This 
excludes a possibility that the lack of complementation be- 
tween class A murine cells and the PNH cell lines was due 
to species incompatibility. 
Deficient Biosynthesis of GlcNAc-PI in SS-1-  and  TK14- 
Cells.  The above results demonstrated that the two PNH 
cell lines belong to complementation class A. We, therefore, 
analyzed biosynthesis of the GPI  anchor intermediates in 
SS-1-, TK-1-, and TK-14-  cells. Since previous studies on 
class A murine thymoma cells indicated that they do not syn- 
thesize GIcNAc-PI, the first intermediate of the biosynthetic 
pathway, we first focused on the early steps of the biosyn- 
thesis. Incubations of the radiolabeled donor of GlcNAc, UDP- 
6-[3H]GlcNAc,  with cell lysates of GPI anchor-sufficient cell 
lines, SS-2 + and TK-4*, established  from the same patients 
as SS-1-  and TK-14- resulted in synthesis of GlcNAc-PI and 
its subsequent deacetylation to glucosaminyl-phosphatidy- 
linositol (GlcN-PI) (Fig. 2, lanes 2 and 4). The identities of 
these spots were confirmed by assessing their sensitivities  to 
PI-PLC and HNO2 (data not shown). In contrast, cell ly- 
sates of deficient cell lines, SS-1 -, TK-1 -, and TK-14-, did 
not support biosynthesis of GlcNAc-PI (Fig.  2, lanes 1, 3, 
and 5), being consistent with the above complementation 
analyses and previous reports on the biosynthetic defect  of 
routine class A  cells. 
Being consistent with these results,  both in vitro and in 
vivo analyses of mannolipid biosynthesis demonstrated that 
these  deficient  cell  lines  are  able  to  synthesize  dolichol- 
phosphate-mannose, a donor of mannose, but are not able 
to synthesize significant amounts of mannose-containing in- 
termediates in GPI anchor biosynthesis (data not shown). 
Discussion 
In the present study we have characterized for the first time 
the exact biochemical defect of affected cells from patients 
with PNH.  We previously established  cell lines from two 
Japanese  patients  with  PNH  (16). The  established  GPI- 
anchored protein-deficient cell lines had the phenotype of 
PNH: (a) deficiency of surface expressions  of multiple GPI- 
anchored proteins; (b) normal transcription of the DAF gene; 
and (c) intraceUular biosynthesis of  precursor peptides of DAF 
and CD59.  To characterize the biochemical defect of these 
GPI anchor-deficient cell lines two approaches  were under- 
taken.  First,  these  cell  lines  were  fused  with  GPI  an- 
chor-deficient mutant cell lines of known biochemical defects 
to assess complementation of the surface expression  of GPI- 
anchored  proteins.  Second,  biosynthesis  of glucosamine- 
containing glycolipids was analyzed in an in vitro system using 
cell lysates and the radioactive sugar nucleotide. The com- 
plementation analysis demonstrated that both cell lines had 
the same defect as mutant cells of class A, which is one of 
the three "early mutants" that do not synthesize GlcNAc-PI 
(Fig.  I  and Table 1). The biosynthetic analysis provided in- 
dependent and consistent evidence that GlcNAc-PI is not syn- 
thesized in these PNH cell lines (Fig. 2). It is, therefore, con- 
cluded that an early step in the biosynthesis of GPI anchor 
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Japanese  patients. 
It seems reasonable  to assume that a defect in any one of 
the genes in the biosynthetic  pathway of  the GPI anchor causes 
a similar clinical disorder.  Previous  analysis of the GPI an- 
chor biosynthesis in  the affected  neutrophils from several 
American patients with PNH indicated that biosynthesis of 
GIcNAc-PI and its subsequent deacetylation are normal (23), 
but that biosynthesis of mature GPI anchor is markedly re- 
duced or virtually negative in affected neutrophils (4),  sug- 
gesting the presence of an abnormality in the later reaction 
sequence. However, more recent analysis showed that deficient 
T  cell lines obtained from one of these American patients 
and from other patients with PNH do not synthesize GlcNAc- 
PI and belong to complementation class A (Armstrong, C., 
J. Schubert, E. Ueda, J. J. Knez, D. M. Gelperin, S. Hirose, 
R. Silber, S. Hollan, R. E. Schmidt, and M. E. Medof, manu- 
script submitted for publication), and that deficient EBV- 
transformed B cells from another American patient exhibit 
the same defect (Ueda, E., and M.  E.  Medof, manuscript 
in preparation),  suggesting that the apparent in vitro GlcNAc- 
PI synthesis observed  with the neutrophil lysates may have 
occurred as a result of admixture of unaffected cells. It thus 
seems that the biochemical defect of the patients studied in 
America is the same as that of the Japanese patients studied 
here, and is common to most, if not all, of the patients with 
PNH. 
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